Artykuł w czasopiśmie
Brak miniatury
Licencja
CC-BYCC-BY - Uznanie autorstwa
 

Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib

Uproszczony widok
cris.lastimport.scopus2024-02-12T20:55:03Z
dc.abstract.enNearly half of patients with advanced and metastatic melanomas harbor a BRAF mutation. Vemurafenib (VEM), a BRAF inhibitor, is used to treat such patients, however, responses to VEM are very short-lived due to intrinsic, adaptive and/or acquired resistance. In this context, we present the action of the B-Raf serine-threonine protein kinase inhibitor (vemurafenib) on the glycans structure and metallomics profiles in melanoma cells without (MeWo) and with (G-361) BRAF mutations. The studies were performed using α1-acid glycoprotein (AGP), a well-known acute-phase protein, and concanavalin A (Con A), which served as the model receptor. The detection of changes in the structure of glycans can be successfully carried out based on the frequency shifts and the charge transfer resistance after interaction of AGP with Con A in different VEM treatments using QCM-D and EIS measurements. These changes were also proved based on the cell ultrastructure examined by TEM and SEM. The LA-ICP-MS studies provided details on the metallomics profile in melanoma cells treated with and without VEM. The studies evidence that vemurafenib modifies the glycans structures and metallomics profile in melanoma cells harboring BRAF mutation that can be further implied in the resistance phenomenon. Therefore, our data opens a new avenue for further studies in the short-term addressing novel targets that hopefully can be used to improve the therapeutic regiment in advanced melanoma patients. The innovating potential of this study is fully credible and has a real impact on the global patient society suffering from advanced and metastatic melanomas.
dc.affiliationUniwersytet Warszawski
dc.contributor.authorNisiewicz, Monika K.
dc.contributor.authorKowalczyk, Agata
dc.contributor.authorSobiepanek, Anna
dc.contributor.authorJagielska, Agata
dc.contributor.authorWagner, Barbara
dc.contributor.authorNowakowska, Julita
dc.contributor.authorGniadek, Marianna
dc.contributor.authorGrudziński, Ireneusz
dc.contributor.authorKobiela, Tomasz
dc.contributor.authorNowicka, Anna
dc.date.accessioned2024-01-26T11:04:38Z
dc.date.available2024-01-26T11:04:38Z
dc.date.copyright2021-01-03
dc.date.issued2021
dc.description.accesstimeAT_PUBLICATION
dc.description.financePublikacja bezkosztowa
dc.description.number1
dc.description.versionFINAL_PUBLISHED
dc.description.volume22
dc.identifier.doi10.3390/IJMS22010439
dc.identifier.issn1422-0067
dc.identifier.urihttps://repozytorium.uw.edu.pl//handle/item/123635
dc.identifier.weblinkhttp://www.mdpi.com/
dc.languageeng
dc.pbn.affiliationbiological sciences
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.relation.pagesart.no. 439
dc.rightsCC-BY
dc.sciencecloudnosend
dc.subject.enGlycans structure
dc.subject.enMelanoma cells with BRAF mutation
dc.subject.enMetallomics profile
dc.subject.enVemurafenib
dc.subject.enα1-acid glycoprotein
dc.titleTracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib
dc.typeJournalArticle
dspace.entity.typePublication